✦ LIBER ✦

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

✍ Scribed by Dodel, Richard; Rominger, Axel; Blennow, Kaj; Barkhof, Frederik; Wietek, Stefan; Haag, Stefan; Bartenstein, Peter; Farlow, Martin; Jessen, Frank

Book ID: 122524445
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 87 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.09.107

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized double-blind placebo-controll

Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

✍ Farlow, Martin R.; Jessen, Frank; Wietek, Stefan; Melsen, Tina; Haag, Stefan; Do 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Intravenous immunoglobulin for treatment

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

✍ Dodel, Richard; Rominger, Axel; Bartenstein, Peter; Barkhof, Frederik; Blennow, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 746 KB

Brain glucose metabolism in patients wit

Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study

✍ Rominger, Axel; Foerster, Stefan; Zach, Christian; Dodel, Richard; Blennow, Kaj; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 153 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre